-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$9.86224.34% Upside
Recent Analyst Forecasts and Stock Ratings
Fulcrum Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Fulcrum Therapeutics, Inc.?
Fulcrum Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright, RBC Capital, Stifel Nicolaus, Bank of America Securities, Cantor Fitzgerald, Goldman Sachs in the past 90 days.